Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 1969245.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mean ratings of positive and negative symptoms and depression significantly improved in nine treatment-resistant schizophrenic patients who completed a 6-week open trial of fluoxetine added to their neuroleptics. The authors identify differences between responders and nonresponders and recommend controlled trials.
Medical subject headings
- Antipsychotic Agents
- Fluoxetine
- Schizophrenia